When society gets ravaged by diseases, progress becomes much of a challenge. In the 19th Century, existing health care was not for a single moment dependable since, at the time, scientists were still discovering how to make life bearable. However, the arrival of the 20th Century saw much progress in healthcare, with innovation contributing significantly to most medical breakthroughs. Although most ailments that affected the 19th and 20th Century civilizations are now treatable, there are other ‘special diseases’ that have become more of a nightmare to contain (http://www.marketwatch.com/investing/stock/fold). Current statistics show that around 350 million individuals suffer from rare diseases globally. Since the orphan diseases have proven to be almost impossible to cure, patients suffering from such maladies have often experienced a lot of stigmas and social alienation.



However, their plight has not gone unnoticed. With the creation of Amicus Therapeutics, much progress has come about in assisting the patients with rare diseases to lead normal and productive lives. From the get go, Amicus Therapeutics has categorically invested its resources in facilitating research exercises meant to bring the realization of cures to ailments like Pompe Disease, Lysosomal Storage Disorders Fabry, and Epidermolysis Bullosa closer. Since 2002, Amicus Therapeutics has successfully come up with Migalastat, a drug ideal for the treatment of Fabry Disease. Moreover, SD-01 has helped in the treatment and therapy of Epidermolysis Bullosa, thus making individuals suffering from the disease regain their dignity.



Since Amicus Therapeutics has worked tooth and nail to assist members of the community with their health problems, society has, in turn, reciprocated a lot of positivity that has led to the growth and expansion of the corporation. Today, Amicus Therapeutics has international branches in regions like the United Kingdom, Italy, France, Spain, Germany, and the Netherlands. Apart from that, Amicus Therapeutics has since expanded to become an employer of more than 500 individuals in its many branches across the globe. What Amicus has been doing for the last fifteen years is a step in the right direction. As per now, society is more aware that individuals suffering from rare diseases also have the right to enjoy their ‘freedom of love and affection’ that the unseen forces of nature have so generously given to us (Glassdoor).